Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT02210871 · Completed

Last updated 2026-05-28

This clinical trial is testing how a single injection of semaglutide is processed by the body and its safety in adults with mild, moderate, or severe liver problems compared to those with normal liver function.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 44 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-08 · est. completion 2015-06

Where 4 sites · Poland, Slovakia

What this study is testing ClinicalTrials.gov NCT02210871 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability after a single injection of semaglutide in subjects with mild, moderate or severe hepatic impairment compared to subjects with normal hepatic function.

Treatments tested

semaglutide Drug

All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.

Main thing measured	Area under the semaglutide plasma concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02210871 ↗